Activation of protein kinase C increases Ca2+ sensitivity of secretory response of GH3 pituitary cells.
The effect of protein kinase C on the secretory response of GH3 pituitary cells to Ca2+ was investigated. Activation of protein kinase C with 100 nM 12-O-tetradecanoylphorbol 13-acetate (TPA) for 40 min reduced the rise in intracellular free calcium concentration ([Ca2+]i) stimulated by depolarization with high K+ but did not affect the threefold increase in prolactin secretion stimulated by 50 mM K+. Both [Ca2+]i and prolactin release were measured for control and TPA-treated cells over a range of [Ca2+]i values attained by adding the acetoxymethyl ester of 1,2-bis(2-aminophenoxy)-ethane -N,N,N',N'- tetraacetic acid (BAPTA/AM) to reduce [Ca2+]i or high K+ with or without BAY K 8644 to increase [Ca2+]i. Half-maximal prolactin secretion occurred at lower [Ca2+]i concentrations for cells treated with TPA (approximately 160 nM) than for control cells (approximately 270 nM), but the rate of secretion at high [Ca2+]i was the same. GH3 cells also secreted more prolactin in response to thyrotropin-releasing hormone (TRH) after protein kinase C activation, although TRH evoked a smaller Ca2+ transient. Fluorescence ratio imaging revealed that GH3 cells undergo spontaneous [Ca2+]i oscillations (4-12/min) and that TPA nearly abolishes [Ca2+]i oscillations as well as inhibits the increase in [Ca2+]i stimulated by depolarization. These results demonstrate that activation of protein kinase C increases the Ca2+ sensitivity of the secretory response in GH3 cells, causing up to a twofold increase in the rate of secretion at typical intracellular Ca2+ concentrations.
Haymes
A A
AA
Department of Pharmacology, University of Rochester School of Medicine and Dentistry, New York 14642.
Hinkle
P M
PM
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004789:Enzyme Activation; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D010911:Pituitary Neoplasms; D011189:Potassium Chloride / Q000494:pharmacology; D011388:Prolactin / Q000378:metabolism*; D011493:Protein Kinase C / Q000378:metabolism*; D051381:Rats; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology; D014407:Tumor Cells, Cultured
C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D004533:Egtazic Acid; D013973:Thyrotropin-Releasing Hormone; D004815:Epidermal Growth Factor; D011189:Potassium Chloride; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D011388:Prolactin; D066246:ErbB Receptors; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium